- Conditions
- CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
- Interventions
- Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution
- Drug
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 80
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Nephropathy
- Interventions
- SPP301
- Drug
- Lead sponsor
- Speedel Pharma Ltd.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 2,364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Diabetic Nephropathy, Chronic Kidney Disease
- Interventions
- Zemplar (paricalcitol) capsules, Placebo
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Yuba City, California + 21 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Neo-kidney augment
- Biological
- Lead sponsor
- Tengion
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • New Orleans, Louisiana • Boston, Massachusetts + 2 more
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
- Interventions
- BYDUREON, Placebo
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Diabetic Nephropathies
- Interventions
- PF-00489791, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 63
- States / cities
- Huntsville, Alabama • Glendale, Arizona • Tempe, Arizona + 46 more
- Conditions
- Diabetic Kidney Disease, Diabetes Type 2, Chronic Kidney Diseases, Healthy
- Interventions
- Not listed
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 40 participants
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Woburn, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperlipidemia
- Interventions
- Extended release niacin, Placebo
- Drug · Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Chronic Kidney Diseases
- Interventions
- Zibotentan, Dapagliflozin, Placebo, Dapagliflozin and Zibotentan
- Drug
- Lead sponsor
- University Medical Center Groningen
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Chronic Kidney Disease, Diabetic Nephropathy Type 2, Kidney Failure, Kidney Insufficiency
- Interventions
- Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose, Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose
- Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine
- Interventions
- ABT-614, Placebo Comparator
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes Mellitus
- Interventions
- Finerenone (Kerendia, BAY948862), Others except finerenone
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 238,038 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease
- Interventions
- Renal Autologous Cell Therapy (REACT)
- Biological
- Lead sponsor
- Prokidney
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Boise, Idaho • Chapel Hill, North Carolina + 1 more
- Conditions
- Heart Failure, Type 2 Diabetes, Chronic Kidney Diseases
- Interventions
- Virtual Consult Intervention
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
- Interventions
- Bardoxolone methyl (amorphous dispersion)
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 26
- States / cities
- Montgomery, Alabama • Phoenix, Arizona • Tempe, Arizona + 23 more
- Conditions
- Chronic Kidney Disease, Diabetic Nephropathy
- Interventions
- Placebo for Atrasentan 0.2 mg/mL solution, 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD, 1.75 mg Atrasentan QD
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 24
- States / cities
- Tempe, Arizona • Azusa, California • Los Angeles, California + 16 more
- Conditions
- Diabetes Mellitus, Metabolic Syndrome, Obesity, Hypertension,Essential, Hyperlipidemias, Cardiovascular Diseases, Kidney Disease, Chronic
- Interventions
- Lifestyle Medicine Program, Medically Tailored Groceries
- Behavioral
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes Mellitus, Heart Failure
- Interventions
- sMRA therapies
- Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey
- Conditions
- Diabetic Kidney Disease (DKD)
- Interventions
- ALN-ANG3, Evinacumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 58
- States / cities
- Huntsville, Alabama • Little Rock, Arkansas • Huntington Beach, California + 47 more
- Conditions
- Diabetes, Kidney Diseases
- Interventions
- Continuous Glucose Monitoring
- Device
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Great Neck, New York
- Conditions
- Chronic Kidney Disease, Diabetes, Hypertension, High BP, Type 2 Diabetes
- Interventions
- Collaborative Model of Primary care and Subspecialty care
- Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 18,268 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 4
- States / cities
- Farmington, Connecticut • Arlington, Texas • Dallas, Texas
- Conditions
- Chronic Kidney Diseases, Diabetic Kidney Disease
- Interventions
- KidneyIntelX
- Diagnostic Test
- Lead sponsor
- Renalytix AI, Inc.
- Industry
- Eligibility
- 23 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
- Interventions
- Computer assisted education and motivational interviewing., Group talks/social chat
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Denver, Colorado
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Oral semaglutide, Sitagliptin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 43,650 participants
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts